Novo Nordisk tumbles as Wegovy sales miss, trial setback overshadow raised outlook
Go back to Novo Nordisk tumbles as Wegovy sales miss, trial setback overshadow raised outlook| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1224.24 -7.7 (0.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1231.94 | 52 Week High | $88.16 | |||
| Open | $1230.65 | 52 Week Low | $67.88 | |||
| Day High | $1238.00 | P/E | 283.39 | |||
| Day Low | $1210.01 | EPS | $4.32 | |||
| Volume | 719,363 | |||||
| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 47.10 -0.63 (1.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $47.73 | 52 Week High | $59.00 | |||
| Open | $47.45 | 52 Week Low | $32.80 | |||
| Day High | $47.67 | P/E | N/A | |||
| Day Low | $47.10 | EPS | $0.00 | |||
| Volume | 3,323,909 | |||||
